<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Doxorubicin has been widely used to treat many cancers. It also induces cumulative and delayed cardiomyopathy. New biological markers to predict cardiac toxicity is needed.Objectives: We identified novel markers and potential therapeutic targets of doxorubicin (DOX)-induced cardiac toxicity by proteomics approach.Methods: The protein profiling of H9c2 cells in response to DOX at an apoptosis-induced concentration (0.5⃞M) were compared by two-dimensional electrophoresis (2-DE) and mass spectrometry.Results: A total of nine differently expressed proteins were identified including six up-regulated and three downregulated proteins. We further confirmed the expression of two down-regulated proteins, prohibitin and endoplasmic reticulum protein ERp29 (ERp29), decreased in response to DOX induction by Western-blot, and over-expression of ERp29 also partially recovered the MTT reduction.Conclusion: We first identified ERp29 and prohibitin as novel markers for DOX toxicity, and ERp29 might be a candidate target to develop novel therapeutic strategies to alleviate adverse effects of doxorubicin-based chemotherapies. </abstract>

Background: Doxorubicin has been widely used to treat many cancers. It also induces cumulative and delayed cardiomyopathy. New biological markers to predict cardiac toxicity is needed.Objectives: We identified novel markers and potential therapeutic targets of doxorubicin (DOX)-induced cardiac toxicity by proteomics approach.Methods: The protein profiling of H9c2 cells in response to DOX at an apoptosis-induced concentration (0.5⃞M) were compared by two-dimensional electrophoresis (2-DE) and mass spectrometry.Results: A total of nine differently expressed proteins were identified including six up-regulated and three downregulated proteins. We further confirmed the expression of two down-regulated proteins, prohibitin and endoplasmic reticulum protein ERp29 (ERp29), decreased in response to DOX induction by Western-blot, and over-expression of ERp29 also partially recovered the MTT reduction.Conclusion: We first identified ERp29 and prohibitin as novel markers for DOX toxicity, and ERp29 might be a candidate target to develop novel therapeutic strategies to alleviate adverse effects of doxorubicin-based chemotherapies.

Endoplasmic reticulum protein ERp29 and doxorubicininduced toxicity in H9c2 cardiomyocytes: a comparative proteomics analysis

Central laboratory, Qingdao Municipal Hospital, Qingdao, Shandong 266071,

Department of Cardiology, Qingdao Municipal Hospital, Qingdao, Shandong 266071,

Clinical laboratory, Qingdao Municipal Hospital, Qingdao, Shandong 266071,

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Background: Doxorubicin has been widely used to treat many cancers. It also induces cumulative and delayed cardiomyopathy. New biological markers to predict...

Endoplasmic reticulum protein ERp29 and doxorubicininduced toxicity in H9c2 cardiomyocytes: a comparative proteomics analysis

Article Category: Brief communication (Original)

Published Online: Feb 04, 2017

Page range: 433 - 437

DOI: https://doi.org/10.5372/1905-7415.0603.073

Keywords
Apoptosis, cardiac toxicity, doxorubicin, ERp29, proteomics

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Endoplasmic reticulum protein ERp29 and doxorubicininduced toxicity in H9c2 cardiomyocytes: a comparative proteomics analysis

Article Category: Brief communication (Original)

Published Online: Feb 04, 2017

Page range: 433 - 437

DOI: https://doi.org/10.5372/1905-7415.0603.073

KeywordsApoptosis, cardiac toxicity, doxorubicin, ERp29, proteomics

© 2017

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Keywords
Apoptosis, cardiac toxicity, doxorubicin, ERp29, proteomics